Condition: Castration Resistant Metastatic Prostate Cancer · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
This description comes directly from the study's public registry record.
GU oncology · 4109551239 · ProstateCancerClinicalTrials@live.johnshopkins.edu
Harry Cao, MA · 443-287-6882 · hcao7@jhmi.edu
Always discuss trial participation with your own doctor first.
| University of California, San Diego (UCSD) | San Diego, California, United States | Recruiting |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore, Maryland, United States | Recruiting |
| Dana-Faber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| University of Washington/Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04363164